Quick Answer
AtriCure, Inc. reported R&D Expense of $99.21 million for fiscal year 2025.
AtriCure, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $99.21M | +3.2% |
| 2024 | $96.18M | +30.1% |
| 2023 | $73.92M | +28.9% |
| 2022 | $57.34M | +18.2% |
| 2021 | $48.51M | +12.6% |
| 2020 | $43.07M | +4.5% |
| 2019 | $41.23M | +18.7% |
| 2018 | $34.72M | +1.7% |
| 2017 | $34.14M | -4.7% |
| 2016 | $35.82M | +39.2% |
| 2015 | $25.74M | +38.4% |
| 2014 | $18.60M | +38.4% |
| 2013 | $13.44M | +10.6% |
| 2012 | $12.15M | +2.4% |
| 2011 | $11.86M | +2.8% |
| 2010 | $11.53M | +1.0% |
| 2009 | $11.41M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.89M | +9.2% | -21.8% |
| June 30, 2025 | $29.28M | +43.4% | +30.0% |
| March 31, 2025 | $22.53M | +13.5% | +7.5% |
| September 30, 2024 | $20.96M | +3.0% | +2.7% |
| June 30, 2024 | $20.42M | +17.1% | +2.9% |
| March 31, 2024 | $19.84M | +29.5% | -2.5% |
| September 30, 2023 | $20.35M | +34.2% | +16.7% |
| June 30, 2023 | $17.44M | +17.9% | +13.8% |
- AtriCure, Inc. showed an increase of +3.2% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, AtriCure, Inc.’s r&d expense has grown by 769.1% (from $11.41 million to $99.21 million).
- The most recent figure is from AtriCure, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: